These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31189224)

  • 1. [Consideration on the use of injectable anti-tuberculosis drufgs in the treatment of drug-resistant tuberculosis in china].
    Liu YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Jun; 42(6):401-404. PubMed ID: 31189224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for
    Catanzaro DG; Trollip AP; Seifert M; Georghiou SB; Garfein RS; Rodwell TC; Catanzaro A; Eisenach KD
    Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28381434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of multidrug-resistant tuberculosis in Zunyi, Guizhou Province of China.
    Chen L; Li N; Liu M; Zhang J; Zhang H
    J Antimicrob Chemother; 2011 Oct; 66(10):2435-7. PubMed ID: 21795258
    [No Abstract]   [Full Text] [Related]  

  • 4. [Approaches to combined therapy of pulmonary tuberculosis in adolescents excreting drug-resistant Mycobacterium tuberculosis].
    Firsova VA; Rusakova LI; Grigor'eva ZP; Ryzhova AP; Iatskova TV; Poluéktova FG
    Probl Tuberk; 2001; (1):28-30. PubMed ID: 11337776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The analysis of clinical data about the treatment of linezolid against tuberculosis].
    Nie WJ; Chu NH
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):601-3. PubMed ID: 24252739
    [No Abstract]   [Full Text] [Related]  

  • 6. Trench warfare in a battle with TB.
    Marshall E
    Science; 2008 Jul; 321(5887):362-4. PubMed ID: 18635790
    [No Abstract]   [Full Text] [Related]  

  • 7. pncA mutations are associated with slower sputum conversion during standard treatment of multidrug-resistant tuberculosis.
    Zheng X; Ning Z; Drobniewski F; Yang J; Li Q; Zhang Z; Hu Y
    Int J Antimicrob Agents; 2017 Feb; 49(2):183-188. PubMed ID: 28012685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.
    Dalcolmo M; Gayoso R; Sotgiu G; D'Ambrosio L; Rocha JL; Borga L; Fandinho F; Braga JU; Arakaki Sanchez D; Dockhorn F; Centis R; Migliori GB
    Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28404651
    [No Abstract]   [Full Text] [Related]  

  • 9. Study of primary drug resistance of Mycobacterium tuberculosis from two hospitals in Tenerife, Canary Islands, Spain (1990-1997).
    Lecuona M; Alvarez R; Quintero J; Torres A; Hernández AM; Montesinos I; Sierra A
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):186-7. PubMed ID: 10694101
    [No Abstract]   [Full Text] [Related]  

  • 10. Practical considerations to implement the shorter regimen to MDR-TB patients in China.
    Liu Q; Sun F; Li Y; Bao J; Zhang Y; Zhang W
    Clin Microbiol Infect; 2018 Oct; 24(10):1035-1036. PubMed ID: 29730223
    [No Abstract]   [Full Text] [Related]  

  • 11. Pyrazinamide resistance among drug-resistant Mycobacterium tuberculosis isolates at a referral hospital.
    Arora J; Sidiq Z; Visalakshi P; Bhalla M; Behera D; Myneedu VP
    Diagn Microbiol Infect Dis; 2013 Dec; 77(4):380-1. PubMed ID: 24075630
    [No Abstract]   [Full Text] [Related]  

  • 12. [Control de la tuberculosis multirresistente a fármacos: un objetivo posible].
    Robledo J
    Biomedica; 2019 Sep; 39(3):431-433. PubMed ID: 31584757
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug-resistant tuberculosis.
    Böttger EC
    Lancet; 2001 Apr; 357(9264):1288-9. PubMed ID: 11421208
    [No Abstract]   [Full Text] [Related]  

  • 14. Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?
    Bastard M; Bonnet M; du Cros P; Khamraev AK; Hayrapetyan A; Kimenye K; Khurkhumal S; Dlamini T; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Am J Respir Crit Care Med; 2015 Feb; 191(3):355-8. PubMed ID: 25635495
    [No Abstract]   [Full Text] [Related]  

  • 15. Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates.
    Jain A; Dixit P; Prasad R
    Tuberculosis (Edinb); 2012 Sep; 92(5):404-6. PubMed ID: 22789499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis.
    Cox HS; Sibilia K; Feuerriegel S; Kalon S; Polonsky J; Khamraev AK; Rüsch-Gerdes S; Mills C; Niemann S
    N Engl J Med; 2008 Nov; 359(22):2398-400. PubMed ID: 19038891
    [No Abstract]   [Full Text] [Related]  

  • 17. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates.
    Sun Z; Zhang J; Song H; Zhang X; Li Y; Tian M; Liu Y; Zhao Y; Li C
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1436-41, i. PubMed ID: 20937184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.
    Sotgiu G; Tiberi S; D'Ambrosio L; Centis R; Alffenaar JW; Caminero JA; Abdo Arbex M; Alarcon Guizado V; Aleksa A; Dore S; Gaga M; Gualano G; Kunst H; Payen MC; Roby Arias AJ; Skrahina A; Solovic I; Sulis G; Tadolini M; Zumla A; Migliori GB;
    Eur Respir J; 2016 Nov; 48(5):1503-1507. PubMed ID: 27587544
    [No Abstract]   [Full Text] [Related]  

  • 19. [Diagnostic accuracy of line probe assays for drug-resistant tuberculosis: a Meta-analysis].
    Xu L; Sun YX; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Nov; 39(11):1491-1495. PubMed ID: 30462960
    [No Abstract]   [Full Text] [Related]  

  • 20. How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform?
    Gebhard A; van den Hof S; Cobelens F
    Am J Respir Crit Care Med; 2015 Jul; 192(1):117. PubMed ID: 26131997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.